MedTrace Logo

Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans

NCT01605539 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-11

Study results available
· View outcomes & findings →

Summary

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Conditions

  • Opiate Addiction

Interventions

DRUG

Cannabidiol 400

Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions

DRUG

Cannabidiol 800

Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions

DRUG

Control

Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study

Sponsors & Collaborators

  • Hurd,Yasmin, Ph.D.

    lead INDIV

Principal Investigators

  • Yasmin Hurd, Ph.D. · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01605539 on ClinicalTrials.gov